Cargando…
32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888552/ http://dx.doi.org/10.1093/schbul/sby014.135 |
_version_ | 1783312549026988032 |
---|---|
author | Cotter, David English, Jane Foecking, Melanie Cannon, Mary Rutten, Bart Zammit, Stanley Lewis, Glyn Sabhwerwal, Sophie Lopez, Lorna O’Gorman, Aoife Cagney, Gerard |
author_facet | Cotter, David English, Jane Foecking, Melanie Cannon, Mary Rutten, Bart Zammit, Stanley Lewis, Glyn Sabhwerwal, Sophie Lopez, Lorna O’Gorman, Aoife Cagney, Gerard |
author_sort | Cotter, David |
collection | PubMed |
description | BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In the current study we test the hypothesis that altered complement pathway proteins are associated with persisting psychotic experiences from age 11 to age 18. METHODS: The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved. We studied a subsample of the cohort who participated in psychiatric assessment interviews at age 11 and 18, and who provided plasma samples at age 11. Semi-targeted proteomic profiling was used to specifically assess the complement pathway proteins in age 11 children who experienced psychotic experiences (but not disorder) at age 11 and age 18 (n=39) compared to age 11 children who only experienced psychotic experiences at age 11. RESULTS: 11 of 34 proteins assessed were significantly differentially expressed at p<0.05 and of these 8 remained significant following correction for multiple comparisons. Protein changes were in keeping with increased proteins expression of most complement pathway proteins. Several protein changes represented specific replications of the changes observed in age 11 samples prior to psychotic disorder at age 18, namely increased plasminogen, complement factor H, and complement factor 1r. DISCUSSION: Our findings implicate the blood complement system in the persistence of psychotic experiences from age 11 to age 18. Considering that psychotic experiences are predictive of many psychiatric disorders our findings implicate the complement system not just in psychotic disorders, but more broadly in the vulnerability to a range of adult psychiatric disorders. |
format | Online Article Text |
id | pubmed-5888552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58885522018-04-11 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 Cotter, David English, Jane Foecking, Melanie Cannon, Mary Rutten, Bart Zammit, Stanley Lewis, Glyn Sabhwerwal, Sophie Lopez, Lorna O’Gorman, Aoife Cagney, Gerard Schizophr Bull Abstracts BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In the current study we test the hypothesis that altered complement pathway proteins are associated with persisting psychotic experiences from age 11 to age 18. METHODS: The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved. We studied a subsample of the cohort who participated in psychiatric assessment interviews at age 11 and 18, and who provided plasma samples at age 11. Semi-targeted proteomic profiling was used to specifically assess the complement pathway proteins in age 11 children who experienced psychotic experiences (but not disorder) at age 11 and age 18 (n=39) compared to age 11 children who only experienced psychotic experiences at age 11. RESULTS: 11 of 34 proteins assessed were significantly differentially expressed at p<0.05 and of these 8 remained significant following correction for multiple comparisons. Protein changes were in keeping with increased proteins expression of most complement pathway proteins. Several protein changes represented specific replications of the changes observed in age 11 samples prior to psychotic disorder at age 18, namely increased plasminogen, complement factor H, and complement factor 1r. DISCUSSION: Our findings implicate the blood complement system in the persistence of psychotic experiences from age 11 to age 18. Considering that psychotic experiences are predictive of many psychiatric disorders our findings implicate the complement system not just in psychotic disorders, but more broadly in the vulnerability to a range of adult psychiatric disorders. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888552/ http://dx.doi.org/10.1093/schbul/sby014.135 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Cotter, David English, Jane Foecking, Melanie Cannon, Mary Rutten, Bart Zammit, Stanley Lewis, Glyn Sabhwerwal, Sophie Lopez, Lorna O’Gorman, Aoife Cagney, Gerard 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title | 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title_full | 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title_fullStr | 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title_full_unstemmed | 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title_short | 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 |
title_sort | 32.4 altered complement pathway protein expression is associated with psychotic experiences at age 11 which persist at age 18 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888552/ http://dx.doi.org/10.1093/schbul/sby014.135 |
work_keys_str_mv | AT cotterdavid 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT englishjane 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT foeckingmelanie 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT cannonmary 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT ruttenbart 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT zammitstanley 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT lewisglyn 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT sabhwerwalsophie 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT lopezlorna 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT ogormanaoife 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 AT cagneygerard 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18 |